Tests metformin for weight loss in adults with obesity who do not have diabetes
Compares metformin with a placebo for weight loss in adults with obesity.
Plain-language title generated from the registry record
Registry title: Effect of Metformin Use on Weight Loss in Obese, Non-diabetic People (MOWRI)
Key facts
- Where
- Enugu, NigeriaSee the 2 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 59 years old?
Source: NCT07297290, who can take part
Where in Nigeria
- Pathology FacilityEnugu, NigeriaTaking people
- University of Nigeria Teaching HospitalEnugu, NigeriaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Of Nigeria Teaching Hospital
- Trial code
- NCT07297290
- Record updated
- 22 December 2025
- Original description
Obesity is a chronic disease of global public health concern, contributing to cardiovascular disease, type 2 diabetes and certain cancers. Currently approved anti-obesity drugs and surgery are expensive and not readily available in Nigeria.Read full original descriptionShow less
Effect of Metformin Use on Weight Loss in Obese, Non-diabetic People
Obesity is a chronic disease of global public health concern, contributing to cardiovascular disease, type 2 diabetes and certain cancers. Currently approved anti-obesity drugs and surgery are expensive and not readily available in Nigeria.
Metformin, approved for type 2 diabetes, has been shown to promote weight loss among obese patients in high income countries. However, metformin's effects have not yet been demonstrated in Black African populations, which may have different genetic and environmental predispositions to obesity and to the effect of metformin. This blinded, placebo-controlled, randomized trial is determining the effect of metformin on weight loss, cardiovascular disease risk and insulin resistance in Black Nigerians.
Inclusion: • Obesity (defined as body mass index ≥ 30kg/m2),; Fasting plasma glucose (<7.0mmol/L); No medical treatment for weight control in the previous 12 months; No participation in a current clinical trial.
Exclusion: • Obesity (defined as body mass index ≥ 30kg/m2),; Fasting plasma glucose (<7.0mmol/L); No medical treatment for weight control in the previous 12 months; No participation in a current clinical trial.